HOB BIOTECH(SH:688656) Xin Lang Cai Jing·2025-09-15 02:06Core Viewpoint - The stock of Jiangsu Haobio Pharmaceutical Co., Ltd. experienced a decline of 5.42% on September 15, closing at 157.01 CNY per share, with a trading volume of 106 million CNY and a turnover rate of 1.05%, resulting in a total market capitalization of 9.967 billion CNY [1] Company Overview - Jiangsu Haobio Pharmaceutical Co., Ltd. was established on June 8, 2009, and is located at No. 9, Dongyanli Road, Suzhou Industrial Park. The company was listed on January 13, 2021 [1] - The main business involves the research, production, and sales of in vitro diagnostic reagents. The revenue composition is as follows: reagent sales account for 89.46%, other sales for 5.86%, instrument sales for 3.84%, and rental sales for 0.85% [1] Fund Holdings - According to data, one fund under Shenwan Hongyuan holds a significant position in Haobio. The Shenwan Hongyuan Medical Pioneer Stock A (005433) held 56,100 shares in the second quarter, representing 5.74% of the fund's net value, making it the sixth-largest holding [2] - The fund was established on November 16, 2020, with a current scale of 120 million CNY. Year-to-date returns are 5.7%, ranking 3857 out of 4222 in its category; over the past year, returns are 25.13%, ranking 3518 out of 3802; since inception, the fund has incurred a loss of 43.08% [2] - The fund manager, Yao Hongfu, has been in position for 3 years and 60 days, with the total asset scale currently at 133 million CNY. The best fund return during his tenure is -23.18%, while the worst is -24.16% [2]